Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Contrafect (CFRX)

Contrafect (CFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Contrafect 28 WELLS AVENUE 3RD FLOOR YONKERS NY 10701 USA

www.contrafect.com P: 914-207-2300

Description:

ContraFect Corporation is a biotechnology company. The Company is focused on protein and antibody therapeutic products for life-threatening infectious diseases. Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation is headquartered in Yonkers, New York.

Key Statistics

Overview:

Market Capitalization, $K 535
Enterprise Value, $K -8,375
Shares Outstanding, K 10,705
Annual Sales, $ 0 K
Annual Net Income, $ -65,150 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,360 K
EBIT, $ -30,220 K
EBITDA, $ -29,300 K
60-Month Beta 0.29
% of Insider Shareholders 0.62%
% of Institutional Shareholders 7.85%
Float, K 10,639
% Float 99.38%
Short Volume Ratio 0.15

Growth:

1-Year Return -99.56%
3-Year Return -99.99%
5-Year Return -100.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 57.78%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.50 on 11/14/23
Latest Earnings Date 11/13/23
Earnings Per Share ttm -19.27
EPS Growth vs. Prev Qtr 74.23%
EPS Growth vs. Prev Year 98.55%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-80 on 02/15/23

CFRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -138.70%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.54
Interest Coverage -2.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar